Publications
58
Citations
730
Est. group size
~1
Recurring co-author estimate
Active years
15
Publishing since 2011
Saira Farid's work centers on clinical oncology, with a strong focus on lung cancer treatment strategies including immunotherapy, targeted therapies (like osimertinib and alectinib), and their outcomes and side effects. The research also touches on related areas such as blood clotting disorders (thrombosis), kidney complications, and disparities in cancer treatment access and outcomes, often using retrospective patient data and case reports.
Publication output was higher earlier in the decade (2017-2020) and has slowed in recent years, averaging about 2.4 papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Association Between Socio-Economic Factors and Kidney Transplantation Activity Across Muslim Majority Countries
American Journal of Transplantation · 2025
- Evolving Trends in Organ Donation and Transplantation Rates Across Muslim Majority Countries in the Last Decade
American Journal of Transplantation · 2025
- Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Journal of Thoracic Oncology · 2024
- EP.12B.10 Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology · 2024
- EP.12A.04 Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer
Journal of Thoracic Oncology · 2024
- Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
Hematology Reports · 2023
- MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC
Journal of Thoracic Oncology · 2023
- CGE23-070: Baseline Neutrophil to Lymphocyte Ratio and Its Change Over Time Predict Overall Survival in Metastatic Non–Small Cell Lung Cancer Patients Who Received First Line Pembrolizumab Therapy
Journal of the National Comprehensive Cancer Network · 2023
- Real world outcomes of patients treated with first line chemo-immunotherapy (IO) for small cell lung cancer (SCLC): Impact of brain metastases and patterns of subsequent therapy.
Journal of Clinical Oncology · 2023
- Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses
World Journal of Clinical Oncology · 2021
- Acute Kidney Injury Secondary to Rhabdomyolysis and COVID-19: A Case Report and Literature Review
Case Reports in Nephrology · 2021
- Hereditary Apolipoprotein A-I–Associated Cardiac Amyloidosis
JACC Case Reports · 2021
- Immunotherapy in lung cancer
Journal of Surgical Oncology · 2021
- P09.25 Role of Immune Checkpoint Inhibitors (ICPi) in KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology · 2021
- Immune Checkpoint Inhibitor-induced Fanconi Syndrome
Cureus · 2020
- Journal of Thoracic Oncology×6
- Open Forum Infectious Diseases×6
- BMJ Case Reports×5
- Journal of Clinical Oncology×4
- Mayo Clinic Proceedings×3
- D. Carbone
Medicine · The Ohio State University
- Carly Pilcher
Medicine · The Ohio State University
- Jing Su
Medicine · Indiana University
- Logan Roof
Medicine · The Ohio State University
- Misty Dawn Shields
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile